🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This real-word study is designed to prospectively explore whether local tre...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2024-11-10
Trial ID
NCT06690541
Treatments Being Tested
This trial is testing two novel combinations (temozolomide plus osimertinib...
Status
Completed
Location
University of Colorado Hospital
Start Date
2020-10-29
Trial ID
NCT04541407
Treatments Being Tested
A Phase 2, multi center, open label, dual cohort study to evaluate the effi...
Status
Completed
Location
Gaoxin Hospital of The First Affilated Hospital of Anhui Medical University
Start Date
2019-04-28
Trial ID
NCT03909971
Treatments Being Tested
Lorlatinib is a third-generation, oral, reversible, ATP-competitive, macroc...
Status
Completed
Location
The Gujarat Cancer and Research Institute
Start Date
2020-08-27
Trial ID
NCT04541706
Treatments Being Tested
The purpose of this study is to estimate the effect of rifampin on the sing...
Status
Completed
Location
Pfizer New Haven Clinical Research Unit
Start Date
2016-07
Trial ID
NCT02804399
Treatments Being Tested
This study will test the safety of the combination of ramucirumab and lorla...
Status
Active Not Recruiting
Location
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Start Date
2023-08-17
Trial ID
NCT06007937
Treatments Being Tested
This project was designed To explore the pathological complete response (pC...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2024-11-15
Trial ID
NCT06682884
Treatments Being Tested
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Pos...
Status
Recruiting
Location
Institut Curie
Start Date
2025-01-20
Trial ID
NCT06487078
Treatments Being Tested
Lorlatinib is a novel inhibitor across ALK variants, including those resist...
Status
Completed
Location
Children's Hospital Los Angeles
Start Date
2017-09-05
Trial ID
NCT03107988
Treatments Being Tested
A phase 3 study to demonstrate whether lorlatinib given as monotherapy is s...
Status
Active Not Recruiting
Location
Florida Cancer Specialists
Start Date
2017-04-27
Trial ID
NCT03052608
Treatments Being Tested